Roboligent reports $2.5M offering to one investor as robots move beyond rehab
A September 8 SEC filing reports one investor; the company also completed a $1.8M Air Force rehabilitation project in June.
By RuntimeWire Staff · Published
Primary source: SEC
Why it matters
Roboligent is testing whether one force-control stack can support rehabilitation and factory robots. The $2.5 million offering adds private capital alongside a completed Air Force research program, while adoption, revenue and regulatory status remain undisclosed.
Roboligent, the Round Rock, Texas robotics developer founded by Bongsu Kim, reported a fully sold $2.5 million offering in a Form D filed with the SEC on September 8.
The filing reports one investor but does not identify that investor or disclose Roboligent's valuation. It describes the offering under Rule 506(b) and classifies the securities as an option, warrant or other right to acquire another security, along with "other." The filing does not establish the precise date on which the securities were sold or the offering closed.
Kim has been working on the underlying problem for considerably longer than the financing. He earned his doctorate at the University of Texas at Austin, where he worked on HARMONY, a two-arm rehabilitation exoskeleton designed to help people with stroke, spinal injuries and other severe disabilities perform upper-body movements. The system used force and torque control to adjust how firmly it guided a patient through an exercise.
That research established the technical thread Kim has carried through Roboligent since founding it in 2016: robots that can make controlled physical contact with people and objects rather than staying behind a cage.
One investor, one offering
The new filing is separate from a 2024 Form D in which Roboligent reported selling $2 million of a planned $2.5 million offering to two investors. The September filing is a new notice and reports one investor.
Together, the two filings document $4.5 million in private securities sales since August 2024. That figure excludes Roboligent's federal research awards, which are non-dilutive contracts and grants rather than venture investment. Roboligent also raised $383,444 through a 2021 StartEngine crowdfunding campaign.
The latest Form D offers little financial context beyond the transaction. Current revenue, customers, deployed units, pricing and headcount are not established in the supplied materials. The filing does not specify how the proceeds will be used.
A single investor buying the entire offering makes the round unusually concentrated. The filing does not distinguish whether that backer is an institution, strategic investor or individual.
From an exoskeleton to a therapy assistant
Roboligent's rehabilitation system translates Kim's academic work into a mobile robotic arm connected to a patient's arm or leg through a brace. The product is marketed as REGEN on Roboligent's website and described as Optimo in federal award records.
A therapist can use a touchscreen to teach the system a patient-specific movement, set the number of repetitions and have the robot replay the exercise while providing assistance. Roboligent says the platform can support arm, knee, leg and gait exercises, track movement and strength, and reduce the amount of continuous supervision required from a therapist.
Those remain Roboligent's product claims. The financing filing establishes neither regulatory clearance nor clinical efficacy, customer adoption or revenue. Roboligent's website describes REGEN as a medical device intended for hospitals and clinics, but the materials reviewed for this financing do not establish its current regulatory status.
The Air Force funded the next iteration
The Department of the Air Force gave Roboligent a route to develop the rehabilitation platform without relying entirely on equity capital. An AFWERX STTR Phase II purchase order, awarded in September 2024, carried a value of up to $1,799,035 and paired Roboligent with UT Austin as the research institution.
The federal project involved adapting Optimo for military rehabilitation, including treatment of musculoskeletal injuries and stroke recovery. The contract record lists the project as completed on June 16, 2026.
Roboligent's September 2024 announcement described the award as approximately $1.8 million in AFWERX STTR Phase II funding. The supplied materials characterize the award as non-dilutive government funding rather than venture investment.
The same arms have a factory job
Roboligent is also taking its force-control work beyond rehabilitation. Its product lineup includes Robin, a mobile, two-arm robot pitched for industrial use.
The industrial push broadens Kim's original thesis without abandoning it. Rehabilitation robots must regulate force around vulnerable patients. Factory robots working beside people and handling varied objects face a related contact-control problem, although the purchasing cycles, safety requirements and economics differ sharply.
Running both efforts gives Roboligent two possible commercialization paths for the same core engineering. It also places Roboligent in two capital-intensive markets at once. Medical robotics requires evidence, regulatory work and clinical distribution. Industrial robotics requires reliable hardware, integration and repeatable deployments. The Form D does not show which path the investor is prioritizing.
The financing gives Kim additional capital for work that has moved force-controlled robotics from a university exoskeleton into rehabilitation and industrial systems. The next measure is commercial: whether Roboligent can turn research contracts and technically credible prototypes into repeatable sales. The filing confirms that one backer put $2.5 million behind that attempt.